Muse Stem Cells · An Explainer
The stem cells that find the damage — and go there.
Muse cells are a rare, pluripotent-like subpopulation hiding inside ordinary stem cells — only about 1–5% of them. Given by IV, they follow your body's own distress signal to injured tissue. This page explains what they are, how they differ from regular stem cells, and how they're dosed — with short videos from our YouTube channel throughout.
- Verified authentic — every lot documented at ≥70% SSEA-3+ purity
- Given by IV infusion or targeted injection, depending on what is being treated
- Honest about the evidence — promising early research, but investigational, with no completed Phase 3 trial
Muse cell therapy is investigational and not FDA-approved. It is not a cure, and results vary.

The basics
What are Muse stem cells?
Muse stands for Multilineage-differentiating Stress-Enduring cells. They were identified by researchers in Japan as a small, remarkable subpopulation living inside ordinary mesenchymal stem cells (MSCs) — and they behave differently from any other adult stem cell studied so far.
In a standard MSC preparation, Muse cells are just the SSEA-3–positive fraction — roughly 1 to 5 cells in every 100. A Muse treatment isolates and concentrates that specific fraction, so instead of getting a preparation that is 95%+ ordinary MSCs, you get the cells the research is actually about.
Authentic Muse treatments use Dezawa MuseCells®, sourced through MCI-authorized supply partners, with lot-level documentation for every treatment — see the verification section below for exactly what to ask any clinic for.
Why they're different
Four properties no ordinary MSC has
These are what separate Muse cells from conventional MSCs — and from other pluripotent platforms like embryonic stem cells and iPSCs.
Pluripotent-like
They can differentiate into virtually any cell type in the body — not just mesenchymal lineages. And they do it spontaneously in the body, in response to the local tissue environment, without genetic engineering or chemical induction.
They home to damage
Muse cells actively seek out tissue damage by following sphingosine-1-phosphate (S1P), a distress signal injured cells produce. That homing is what makes simple IV delivery clinically viable in a way it isn't for conventional MSCs.
Immune-privileged
They express HLA-G and produce immunomodulatory factors that calm the host immune response — enabling donor-to-patient (allogeneic) use without HLA matching or immunosuppressive drugs.
Stress-enduring, non-tumorigenic in studies
Muse cells survive harsh, damaged-tissue environments that kill other cells. And despite genuine pluripotency, they have not formed teratomas in published research — backed by low telomerase activity and a somatic-like cell cycle profile.
Watch & learn
Muse cells, in short videos
Four short videos from the Age Well Dr YouTube channel, each on a condition Muse cells are being studied for. They are introductions, not proof — the research behind every one of these areas is early and investigational.
Muse Stem Cells for Stroke
Watch on YouTube →Muse Stem Cells in ALS
Watch on YouTube →Muse Stem Cells for Cardiac Damage
Watch on YouTube →Muse Stem Cells for Hair Growth
Watch on YouTube →Side by side
Muse vs. regular MSCs vs. exosomes
All three are part of regenerative medicine, but they are not interchangeable — they work in completely different ways.
| Muse CellsDezawa MuseCells® | MSC Stem CellsUmbilical cord | Exosomes (EVs)Extracellular vesicles | |
|---|---|---|---|
| What they are | Living cells — the rare SSEA-3+ pluripotent-like subpopulation within MSCs | Living, intact stem cells from umbilical cord tissue | Not cells at all — microscopic lipid “bubbles” (30–150 nm) secreted by stem cells |
| How they work | Home to damage via the S1P signal, then differentiate in place and modulate the immune response | Act as living “bioreactors,” releasing tailored healing signals in response to the tissue environment | Pure messengers — deliver growth factors, cytokines and microRNA that instruct your own cells to repair |
| Can become other cell types? | Yes — cells of all three germ layers, in published research | Limited to mesenchymal lineages (bone, cartilage, fat, muscle) | No — they carry no DNA and cannot replicate or become cells |
| How given | Mainly IV in clinical trials; also direct injection to a target site | IV infusion or direct injection | IV infusion |
One important rule: Muse cells and conventional MSCs are not given together — see “Don't mix them” in the next section.
How treatment is given
IV infusion, injection — or both?
Tap a route to see when it's used. The route is chosen based on what is being treated — a single damaged joint is a different problem from a whole-body one.
Why IV is the best-studied route
IV delivery is supported by the broadest published clinical trial evidence for Muse cells, because it works through the systemic homing mechanism — the cells circulate, sense the S1P distress signal, and migrate to where the damage is.
- Preferred for systemic, neurological, cardiac and immune-related goals
- Best choice when there is no single accessible target
- A simple infusion in our office — no surgery, no anaesthesia
What the IV evidence looks like
The most extensive Muse dataset comes from Phase II trials in Japan, which used a single IV dose of 15 million cells. That trial experience — not marketing — is the foundation of how Muse cells are dosed in the US today.
- Donor cells — no harvesting from your own body, no waiting
- No HLA matching or immune-suppressing drugs needed
When a direct injection is preferred
When the treatment target is one specific, accessible site — a worn knee, a damaged shoulder, a section of spine — injecting the cells directly there gives the strongest, most reliable local effect, because the full dose arrives at the target instead of distributing systemically first.
- Typical local dose: 5–20 million cells, at provider discretion
- Best for orthopaedic and musculoskeletal targets
- Local treatment also produces some systemic effect
What it feels like
A targeted injection is an in-office procedure. Most patients describe it as comparable to other joint injections they've had — the visit is short, and you walk out the same day.
- No hospital, no general anaesthesia
- Aftercare instructions given before you leave
IV + injection together
For complex cases — say, a badly damaged joint plus a systemic goal — a combined approach is reasonable: a concentrated local dose where the damage is, plus IV delivery for whole-body distribution.
- Used when both local effect and systemic coverage are clinically warranted
- Planned case by case by the treating physician — never a default
The honest caveat
The combined approach has not been evaluated in a controlled trial — that comes straight from the clinical literature summary. It is worth knowing what the evidence does and doesn't support before choosing it.
Don't mix Muse cells with regular MSCs
Conventional MSCs suppress the S1P signal Muse cells use to find damaged tissue, so giving both together (or close together) defeats the very mechanism that makes Muse cells distinct. If both are ever part of a treatment plan, they go in separate, spaced treatment cycles — never combined. Any clinic offering a “Muse + MSC cocktail” in the same visit is telling you something about itself.
Dosing, honestly
How many cells — and how anyone actually knows
Most clinic pages either hide dosing or state it like settled fact. Here it is with the uncertainty left in.
The trial dose
Phase II trials in Japan — the largest Muse dataset — used 15 million cells IV, sized for the Japanese patient population.
The US starting dose
For Western patients, 20 million cells IV is the standard starting dose used by MCI-authorized clinical partners, adjusted for larger average body size.
The IV range
Standard IV dosing runs 20–100 million cells depending on the case. Muse doses are built in 5-million-cell increments.
The local dose
For a direct orthopaedic injection to a single site, 5–20 million cells is the general range, set by provider discretion.
Protect yourself
How to verify you're getting authentic Muse cells
“Muse” is becoming a marketing word. Clinics can relabel ordinary MSCs as Muse cells, and a patient in the chair can't tell the difference by looking. The paperwork can. Before trusting any clinic, ask for this:
- Authorized sourcing. The product should come through MCI-authorized supply partners only — ask who the supplier is.
- Lot-level purity documentation showing ≥70% SSEA-3+ — that marker is what makes a cell a Muse cell.
- Viability of 80–90%+ on the same lot paperwork — dead cells don't home to anything.
- The isolation antibody lot — BioLegend #330302 or Thermo Fisher MA1-020. A real supplier can produce this without blinking.
The rule
No SSEA-3 paperwork = not verified Muse cells
Any product that cannot provide SSEA-3 purity documentation should not be administered as Dezawa MuseCells® — it cannot be verified as such, full stop.
Lot documentation should be part of the treatment record — ask to see it. A clinic confident in its supply chain will never be offended by the question.
Candidacy
Who Muse therapy may — and may not — be for
Muse therapy is not for everyone. Candidacy comes down to overall health, how far the damage has progressed, and whether expectations are realistic.
More likely to be a candidate
- In overall good health
- Chronic pain from damaged or degenerated musculoskeletal tissue — joints, spine, or ligaments
- Damage that is significant but not “too far gone”
- Systemic goals where IV homing is the point — decided case by case
- Realistic expectations — looking for a chance to improve, not a guaranteed cure
When we'll likely say no
- Tissue damage that, in the physician's judgment, is too far gone to respond
- Overall health that makes an elective procedure unwise
- Expecting a miracle or a cure — regenerative medicine is neither, and we'd rather lose the sale than take money on a false promise
- Wanting Muse and MSCs in the same visit — the combination defeats the homing mechanism
The process
What treatment involves
Evaluation
A physician reviews the history and imaging — joint, spine, or systemic — and judges whether Muse cells, regular MSCs, or neither is the right call. Not everyone is a candidate, and a good clinic says so.
Dose and route are set
The dose is built in 5-million-cell increments and the route chosen — IV infusion, targeted injection, or both — based on where the damage is and what the evidence supports.
Treatment day
The cells arrive with lot documentation — SSEA-3+ purity and viability on paper — and treatment is given in-office. No surgery, no hospital stay, and you go home the same day.
Questions
Muse stem cells — FAQ
The questions people ask most about Muse cells, answered plainly.
Are Muse stem cells FDA-approved?
No. While regenerative medicine shows promise in a rapidly growing body of scientific data, it has yet to be proven effective and it is not FDA-approved. All procedures at Age Well Dr are entirely elective, and Muse cell therapy should be understood as investigational — the evidence is early, and no Phase 3 trial has been completed.
How are Muse cells different from regular stem cells?
Muse cells are the SSEA-3+ subpopulation within MSCs — roughly 1–5% of them. Unlike conventional MSCs, they are pluripotent-like (able to form cells of all three germ layers in research), they actively home to damaged tissue by following the S1P signal, they are immune-privileged via HLA-G, and they have not formed tumors in published studies despite that pluripotency.
How many cells will I need?
Japanese Phase II trials used 15 million cells by IV. For US patients, 20 million cells IV is the standard starting dose among MCI-authorized partners, with a general IV range of 20–100 million depending on the case, and 5–20 million for a local injection. The dose is set by the treating physician after evaluation — and it's worth being straight about this: the US starting dose is clinical consensus, not the result of a Phase III dose trial.
Can I get Muse cells and regular MSCs at the same time?
No — and be wary of any clinic that offers it. Conventional MSCs suppress the S1P signal Muse cells use to find damaged tissue, so co-administration defeats the homing mechanism. If both products are ever part of your care, they are used in separate, spaced treatment cycles.
How do I know I'm really getting Muse cells?
Ask for the paperwork: sourcing through MCI-authorized supply partners, and lot-level documentation showing ≥70% SSEA-3+ purity and 80–90%+ viability. A product that can't provide SSEA-3 documentation cannot be verified as Dezawa MuseCells®. Lot documentation should be part of the treatment record — ask to see it.
Will it work for me?
Honestly: maybe, and nobody truthful can promise more. Careful clinics only take on patients they believe they have a chance of helping — generally people in good overall health, with chronic pain from damaged musculoskeletal tissue that isn't too far gone. More people are helped than not, but regenerative medicine is not a miracle and it is not a cure. An in-person evaluation is where that judgment gets made for a specific case.
Get in touch
Curious whether Muse cells could help you?
Call or text us and talk with our team about whether Muse cell therapy fits your case — and we'll tell you honestly if it's not the right call.
